Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

AIDS Research and Human Retroviruses

Volumn 16, Issue 18, 2000, Pages 2019-2035

  Bures, R ^a   Gaitan, A ^a   Zhu, T ^b   Graziosi, C ^c   McGrath, K M ^d   Tartaglia, J ^e   Caudrelier, P ^f   El Habib, R ^f   Klein, M ^f   Lazzarin, A ^g   Stablein, D M ^h   Deers, M ^b   Corey, L ^b   Greenberg, M L ^a   Schwartz, D H ⁱ   Montefiori, D C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Virogenetics   (United States)

^f SANOFI PASTEUR   (France)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h EMMES CORPORATION   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANTIBODY RESPONSE; ARTICLE; CANARYPOX VIRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MALE; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; VACCINATION;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; AVIPOXVIRUS; CELL MEMBRANE; GENETIC VECTORS; HETERODUPLEX ANALYSIS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDES; PHYLOGENY; VACCINATION; VACCINES, SYNTHETIC;

EID: 0034634910     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200750054756     Document Type: Article

References (113)

1. Toward an HIV-1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
2. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
3. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies
4. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
5. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
6. The antibody response in HIV-1 infection
7. Clinical trials of candidate AIDS vaccines
8. Candidate AIDS vaccines
9. The prime-boost concept applied to HIV preventive vaccines
10. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus
11. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160
12. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
13. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
14. Core structure of gp41 from the HIV envelope glycoprotein
15. Atomic structure of the ectodomain from HIV-1 gp41
16. The ectodomain of HIV-1 Env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide
17. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
18. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
19. Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor
20. HIV entry and tropism: The chemokine receptor connection
21. Chemokine receptors as HIV coreceptors: Implications and interactions
22. HIV-1 phenotype classified by co-receptor usage
23. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
24. HV entry and its inhibition
25. V3-specific neutralizing antibodies in sera from HIV-1 gp 160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding region of gp120
26. Mechanism of human immunodeficiency virus type 1 (HVI-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
27. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells
28. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
29. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
30. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: Soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120
31. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
32. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
33. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency type 1 isolates
34. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates
35. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell line which the virus is propagated
36. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
37. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
38. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
39. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
40. The antigenic structure of the HIV gp120 envelope glycoprotein
41. A role for carbohydrates in immune evasion in AIDS
42. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies
43. Mne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition
44. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
45. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer
46. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1
47. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120
48. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
49. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
50. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
51. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
52. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
53. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
54. Temporal association of cellular immune responses with initial control of viremia in primary human immunodeficiency virus type 1 syndrome
55. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus
56. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads
57. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection
58. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
59. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
60. The role of the humoral immune response in HIV infection
61. Serologic responses to candidate AIDS vaccines
62. Human trials of HIV-1 vaccines
63. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
64. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
65. SF2 recombinant gp120, or both vaccines in seronegative adults
66. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells
67. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from the CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
68. Induction of immune responses to HIV-1 canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
69. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
70. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
71. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
72. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
73. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
74. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
75. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative pox virus vector system
76. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65), in non-avian species
77. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
78. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
79. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
80. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
81. The recombinant human monoclonal antibody IgGlb12 neutralizes diverse human immunodeficiency virus type 1 primary isolates
82. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgGlb12
83. A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1
84. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
85. Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
86. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
87. The genetic data environment: An expandable GUI for multiple sequence analysis
88. PHYLIP - Phylogeny inference package
89. The neighbour-joining method: A new method for reconstructing phylogenetic trees
90. Phylogenies from molecular sequences: Inference and reliability
91. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection
92. Selection for specific sequences in the external envelope glycoprotein of human immunodeficiency virus type 1 upon primary infection
93. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
94. Gender differences in HIV-1 diversity at time of infection
95. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies
96. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
97. Humoral responses to oligomeric human immunodeficiency virus type 1 envelope protein
98. Characterization of a soluble, oligomeric HIV-1 gp120/gp41 protein as a candidate subunit vaccine
99. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
100. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of their coreceptor usage
101. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
102. Genetic diversity of primary HIV-1 isolates and their sensitivity to antibody-mediated neutralization
103. HIV-1 envelope gene structure and diversity in vivo and following co-cultivation in vitro
104. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations
105. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates
106. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection
107. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines
108. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoproten 160 (MN) followed by a recombinant glycoprotein 160 (MN)
109. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, hostrange-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
110. Memory cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
111. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
112. + cytotoxic T lymphocyte responses in seronegative volunteers